Merck announces compassionate-treatment lottery for Crixivan.
D018791:CD4 Lymphocyte Count; D017326:Clinical Trials, Phase III as Topic; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir; D018579:Patient Selection; D011725:Pyridines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014481:United States
D017320:HIV Protease Inhibitors; D011725:Pyridines; D019469:Indinavir